Share this postThe Drug Development LetterSpecial post-ASCO 2024 edition !Copy linkFacebookEmailNotesMorePlayback speed×Share postShare post at current timeShare from 0:000:00/0:00Transcript6Share this postThe Drug Development LetterSpecial post-ASCO 2024 edition !Copy linkFacebookEmailNotesMore21Special post-ASCO 2024 edition !Timothee Olivier and I discuss the top ASCO 2024 abstracts!Vinay Prasad and Timothée OlivierJun 09, 20246Share this postThe Drug Development LetterSpecial post-ASCO 2024 edition !Copy linkFacebookEmailNotesMore21ShareTranscriptThe Drug Development Letter is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.SubscribeDiscussion about this videoCommentsRestacksShare this postThe Drug Development LetterSpecial post-ASCO 2024 edition !Copy linkFacebookEmailNotesMoreThe Drug Development LetterSubscribeAuthorsVinay PrasadTimothée OlivierRecent PostsThe CABINET studyFeb 21 • Vinay PrasadRANDOMIZED versus REAL-WORLD EVIDENCE ON THE EFFICACY AND TOXICITY OF CHECKPOINT INHIBITORS.Dec 15, 2024 • Timothée OlivierSpecial post-ESMO 2024 edition !Nov 3, 2024 • Vinay Prasad and Timothée OlivierSpecial ESMO 2024 edition !Sep 14, 2024 • Vinay Prasad and Timothée OlivierDriver mutation lung cancerSep 9, 2024 • Vinay PrasadASCO pre-game showMay 30, 2024 • Vinay PrasadCAR T cells linked to secondary AML/MDSDec 24, 2023 • Vinay Prasad
Share this post